Clinical Importance of Treating Iron Overload in Sickle Cell Disease

PHASE3TerminatedINTERVENTIONAL
Enrollment

1

Participants

Timeline

Start Date

April 30, 2009

Primary Completion Date

October 31, 2010

Study Completion Date

December 31, 2010

Conditions
Anemia, Sickle CellTransfusion Hemosiderosis
Interventions
DRUG

deferasirox

Treatment starting dose of 20mg/kg/day based on subjects baseline LIC (liver iron concentration) and gradually escalate the dose to a maximum of 35 mg/kg/day based upon toxicity. Duration is up to a max of 12 months.

Trial Locations (1)

90027

Childrens Hospital Los Angeles, Los Angeles

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Novartis Pharmaceuticals

INDUSTRY

lead

Children's Hospital Los Angeles

OTHER